Table 3.

Incremental cost-effectiveness ratio (cost (€) per QALY gained) of GR risedronate compared with generic risedronate, alendronate, and no treatment for women aged 60–80 years

	GR risedronate
	Vs generic risedronate	Vs alendronate	Vs no treatment
BMD T-score ≤ − 2.5 and prevalent vertebral fractures
60 years	18,295	16,468	12,545
65 years	8067	11,985	3443
70 years	2341	2037	Cost-saving*
75 years	Dominant**	Dominant	Cost-saving
80 years	Dominant	Dominant	Cost-saving
BMD T-score ≤ − 2.5
60 years	55,409	32,790	40,117
65 years	33,664	27,457	22,295
70 years	21,875	12,548	13,707
75 years	Dominant	9811	Cost-saving
80 years	Dominant	Dominant	Cost-saving
Prevalent vertebral fractures
60 years	46,641	43,913	34,963
65 years	33,664	27,457	22,295
70 years	19,922	18,259	13,311
75 years	1682	9585	Cost-saving
80 years	Dominant	Dominant	Cost-saving

*Additional treatment costs lower than fractures-related cost saved with more prevented fractures

**Lower costs for more QALYs